Selgin Tablet (Selegiline 5mg)

What is Selgin Tablet (Selegiline 5mg)?

Selgin Tablet (Selegiline 5mg) is a pharmaceutical formulation containing selegiline hydrochloride, a selective monoamine oxidase-B (MAO-B) inhibitor. It is primarily prescribed to patients with Parkinson’s disease to help manage motor symptoms such as tremors, stiffness, and slowness of movement. By inhibiting the breakdown of dopamine in the brain, Selgin enhances dopaminergic activity, supporting smoother neurological function. It is often used alongside levodopa or as monotherapy in early-stage Parkinson’s to delay the need for more intensive treatment.

Key features

• Active Ingredient — Contains 5mg selegiline HCl per tablet for consistent dosing.
• MAO-B Selectivity — Targets brain enzymes to preserve dopamine without major dietary restrictions.
• Neuroprotective Potential — May slow disease progression in early Parkinson’s.
• Adjunct Therapy — Enhances effectiveness of levodopa in advanced cases.
• Oral Administration — Convenient tablet form for daily use.
• Prescription-Based — Requires medical supervision for safe use.
• Stable Formulation — Shelf-stable under recommended storage conditions.

Who is Selgin Tablet (Selegiline 5mg) for?

This medication is intended for adults diagnosed with Parkinson’s disease, particularly those in the early stages seeking to delay symptom worsening. It may also benefit patients already on levodopa who experience motor fluctuations. Not suitable for individuals with hypersensitivity to selegiline or those on certain antidepressants or stimulants due to interaction risks.

How does Selgin Tablet (Selegiline 5mg) compare?

Compared to standard dopamine precursors like levodopa, Selgin offers a neuroprotective mechanism rather than direct replacement. Unlike non-selective MAO inhibitors, it avoids strict dietary tyramine restrictions. When stacked with other Parkinson’s meds, it enhances efficacy without significantly increasing side effects in most patients. It is less potent than advanced therapies like dopamine agonists but serves as a milder, early-intervention option.